A Randomized Feasibility Clinical Trial of the Management of the Medically-Refractory Motor Symptoms of Advanced Idiopathic Parkinson's Disease With Unilateral Lesioning of the Subthalamic Nucleus Using the ExAblate Transcranial System
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- InSightec
- 入组人数
- 7
- 试验地点
- 1
- 主要终点
- Incidence and Severity of Adverse Events
研究概览
简要总结
This is primarily a safety protocol to evaluate the safety of subthalamotomy using Transcranial ExAblate for treatment of Parkinson's Disease (PD) motor features.
详细描述
This study is designed as a prospective, randomized, double-blind (to subjects and examiners), two-arm (ExAblate treated arm vs ExAblate Sham treated control arm) feasibility study. All treated subjects will be followed for 12 months.
Data will be collected to establish the basic safety and clinical efficacy of this type of treatment as the basis for later studies that will evaluate the full clinical efficacy.
研究设计
- 研究类型
- 干预性
- 分配方式
- 随机
- 干预模型
- 交叉
- 主要目的
- 治疗
- 盲法
- 双盲 (受试者、结局评估者)
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- Men and women, age 30 years and older
- Subjects who are able and willing to give informed consent and able to attend all study visits
- Subjects with a diagnosis of idiopathic PD by UK Brain Bank Criteria as confirmed by a movement disorder neurologist at the site
- Levodopa responsive as defined by at least a 30% reduction in MDS-UPDRS motor sub-scale in the ON vs OFF medication state
- Disabling motor clinical features not optimally controlled by an adequate medication prescription. An adequate medication prescription is defined as a therapeutic dose of each medication or the development of side effects as the medication dose is titrated
- Predominant disability from one side of the body (i.e unilateral or markedly asymmetric disease) as determined by movement disorders neurologist and neurosurgeon
- Subjects should be on a stable dose of all PD medications for 30 days prior to study entry
- Subthalamic nucleus is visible on MRI so that it can be targeted by the ExAblate device
- Subjects should have a Screening motor assessment of ≥ 35 while OFF medications on the MDS-UPDRS
- Subject is able to communicate sensations during the ExAblate Transcranial procedure
排除标准
- Hoehn and Yahr stage in the ON medication state of 2.5 or greater
- Presence of severe dyskinesia as noted by a score of 3 or 4 on questions 4.1 and 4.2 of the MDS-UPDRS
- Presence of other central neurodegenerative disease suspected on neurological examination. These include: multisystem atrophy, progressive supranuclear palsy, corticobasal syndrome, dementia with Lewy bodies, and Alzheimer's disease
- Any suspicion that Parkinsonian symptoms are a side effect from neuroleptic medications
- Subjects who have had deep brain stimulation or a prior stereotactic ablation of the basal ganglia
- Presence of significant cognitive impairment defined as score ≤ 21 on the Montreal Cognitive Assessment (MoCA) or Mattis Dementia Rating Scale of 120 or lower
- Unstable psychiatric disease, defined as active uncontrolled depressive symptoms, psychosis, delusions, hallucinations, or suicidal ideation. Subjects with stable, chronic anxiety or depressive disorders may be included provided their medications have been stable for at least 60 days prior to study entry and if deemed appropriately managed by the site neuropsychologist
- Subjects with significant depression as determined following a comprehensive assessment by a neuropsychologist. Significant depression is being defined quantitatively as a score of greater than 14 on the Beck Depression Inventory
- Legal incapacity or limited legal capacity as determined by the neuropsychologist
- Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse as defined by the criteria outlined in the DSM-IV as manifested by one (or more) of the following occurring within the preceding 12 month period:
- Recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home (such as repeated absences or poor work performance related to substance use; substance-related absences, suspensions, or expulsions from school; or neglect of children or household)
- Recurrent substance use in situations in which it is physically hazardous (such as driving an automobile or operating a machine when impaired by substance use)
- Recurrent substance-related legal problems (such as arrests for substance related disorderly conduct)
- Continued substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance (for example, arguments with spouse about consequences of intoxication and physical fights)
- Subjects with unstable cardiac status including:
- Unstable angina pectoris on medication
- Subjects with documented myocardial infarction within six months of protocol entry
- Significant congestive heart failure defined with ejection fraction < 40
- Subjects with unstable ventricular arrhythmias
- Subjects with atrial arrhythmias that are not rate-controlled
- Severe hypertension (diastolic BP > 100 on medication)
- History of or current medical condition resulting in abnormal bleeding and/or coagulopathy
- Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure
- Subjects with risk factors for intraoperative or postoperative bleeding as indicated by: platelet count less than 100,000 per cubic millimeter, a documented clinical coagulopathy, or INR coagulation studies exceeding the institution's laboratory standard
- Patient with severely impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73m2 (or per local standards should that be more restrictive) and/or who is on dialysis
- Subjects with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.
- Significant claustrophobia that cannot be managed with mild medication
- Subjects who weigh more than the upper weight limit of the MR table and who cannot fit into the MR scanner
- Subjects who are not able or willing to tolerate the required prolonged stationary supine position during treatment
- History of intracranial hemorrhage
- History of multiple strokes, or a stroke within past 6 months
- Subjects with a history of seizures within the past year
- Subjects with brain tumors
- Subjects with intracranial aneurysms requiring treatment or arterial venous malformations (AVMs) requiring treatment
- Are participating or have participated in another clinical trial in the last 30 days
- Any illness that in the investigator's opinion preclude participation in this study
- Subjects unable to communicate with the investigator and staff
- Pregnancy or lactation
- Subjects who have an overall Skull Density Ration lower than 0.40 as calculated from the screening CT
研究组 & 干预措施
ExAblate Treated Arm
ExAblate Transcranial System subthalamotomy for motor symptoms of Parkinson's Disease.
干预措施: ExAblate Transcranial System (Device)
ExAblate Sham Treated Arm
ExAblate Transcranial System sham subthalamotomy for motor symptoms of Parkinson's Disease. Sham subjects completing the 4 Month visit may be offered the actual ExAblate subthalamotomy.
干预措施: ExAblate Transcranial System (Device)
方案终点
主要结局
Incidence and Severity of Adverse Events
时间窗: Baseline to 4 months post treatment
Safety will evaluate the incidence and severity of adverse events associated with ExAblate subthalamotomy for the treatment of Parkinson's Disease motor features.
Mean Change in MDS-UPDRS Part III Scores
时间窗: Baseline to 4 months post treatment
This is a feasibility trial with no hypothesis testing. Primary efficacy will be evaluated using basic summary statistics including comparison of between- and within-group differences in the mean change (from baseline to 4 months) of the motor MDS-UPDRS Part III score for the side contralateral to subthalamotomy in the off-medication condition. For the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Motor Examination), the scores range from a minimum of 0 (no motor symptoms) to a maximum of 132 (severe motor impairment). The Minimal Clinically Important Difference (MCID) for MDS-UPDRS Part III (Motor Examination) generally ranges from 3.25 to 5 points for improvement.
次要结局
- Long Term Adverse Events Profile(Baseline to 12- months post treatment)
试验结果
结果已于 2026-08-13 在 ClinicalTrials.gov 公示。 在 ClinicalTrials.gov 查看
受试者流程
入组 7 人 · 完成 7 人
主要终点
Incidence and Severity of Adverse Events
number of events · 时间窗: Baseline to 4 months post treatment
| 分类 | ExAblate Treated Arm （n=6） | ExAblate Sham Treated Arm （n=1） | Exablate Treated Arm Plus Crossovers （n=7） |
|---|---|---|---|
| Ataxia | 1 | 0 | 1 |
| Dyskinesia | 1 | 0 | 1 |
| Dysarthria | 2 | 0 | 3 |
| Imbalance | 1 | 0 | 1 |
| Musculoskeletal weakness | 2 | 0 | 2 |
| Cognitive disturbance | 1 | 0 | 1 |
| Facial Weakness | 0 | 0 | 1 |
| Persistent falls | 0 | 0 | 1 |
| Hemichorea | 0 | 0 | 1 |
The subject in the Exablate Sham Treated arm crossover after 4 months to actual treatment and included in the group Exablate Treeated arm plus crossovers
Mean Change in MDS-UPDRS Part III Scores
score on the scale MDSUPDR part III · Standard Deviation · 时间窗: Baseline to 4 months post treatment
| 分类 | ExAblate Treated Arm （n=6） | ExAblate Sham Treated Arm （n=1） | Exablate Treated Arm Plus Crossovers （n=7） |
|---|---|---|---|
| Baseline | 50 (12.3) | 38 (0) | 51.7 (12.1) |
| 4 Months | 36.5 (12.7) | 36 (0) | 35.6 (11.8) |
其他终点（2）
Long Term Adverse Events Profile
number of events · 时间窗: Baseline to 12- months post treatment
| ExAblate Treated Arm （n=6） | ExAblate Sham Treated Arm （n=0） | Exablate Treated Arm Plus Crossovers （n=7） |
|---|---|---|
| 0 | — | 2 |
The subject in the Exablate Sham Treated arm crossover after 4 months to actual treatment.
Mean Change in MDS-UPDRS Part IV Scores
score on MDSUPDRS part IV · Standard Deviation · 时间窗: Baseline to 12-months post treatment
| 分类 | ExAblate Treated Arm （n=6） | ExAblate Sham Treated Arm （n=0） | Exablate Treated Arm Plus Crossovers （n=7） |
|---|---|---|---|
| Baseline | 8 (2.7) | — | 8.2 (2.5) |
| 12 Month | 0.25 (0.5) | — | 0.25 (0.5) |
The subject in the Exablate Sham Treated arm crossover after 4 months to actual treatment.
安全性
| 组别 | 严重不良事件 | 死亡 |
|---|---|---|
| ExAblate Treated Arm | 0 / 6 | 0 / 6 |
| ExAblate Sham Treated Arm | 0 / 1 | 0 / 1 |
| Crossover | 1 / 1 | 1 / 1 |
最常见的严重不良事件（人数）
| 事件 | ExAblate Treated Arm | ExAblate Sham Treated Arm | Crossover |
|---|---|---|---|
| Hemichorea | 0 / 6 | 0 / 1 | 1 / 1 |
数值为申办方在 ClinicalTrials.gov 公示的原始数据，未经重新计算；括号内为公示的离散度（如 95% 置信区间）。
研究者
研究点 (1)
标识符
- NCT 编号
- NCT02246374
- 其他研究编号
- PD003
日期
- 首次提交
- (12年前)
- 首次发布
- (12年前)
- 主要完成日期
- (5年前)
- 研究完成日期
- (5年前)
- 最近核实
- (3个月前)
- 最近更新
- (上个月)
监管与共享
- FDA 监管药物
- 否
- FDA 监管器械
- 否
- 是否有结果
- 是